Create Free Account

By creating account you will get access to hot stocks & personalised emails

Healius Ltd

Healthcare AU HLS

1.4AUD
-0.025(1.75%)

Last update at 2024-12-19T05:11:00Z

Day Range

1.351.41
LowHigh

52 Week Range

1.081.86
LowHigh

Fundamentals

  • Previous Close 1.43
  • Market Cap1014.41M
  • Volume1995663
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA106.40M
  • Revenue TTM1746.20M
  • Revenue Per Share TTM2.65
  • Gross Profit TTM 554.30M
  • Diluted EPS TTM-0.96

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -397.30000M 416.90M 167.80M 46.40M 83.20M
Minority interest - - - - -
Net income -367.80000M 307.90M 43.70M -70.50000M 55.90M
Selling general administrative 864.30M 951.40M 856.30M 838.20M 1137.60M
Selling and marketing expenses - - - - -
Gross profit 1483.20M 2019.50M 1630.10M 1381.30M 1598.00M
Reconciled depreciation 277.20M 278.50M 247.30M 218.00M 68.70M
Ebit 34.10M 432.40M 221.40M 56.50M 117.40M
Ebitda 311.30M 710.90M 468.70M 274.50M 186.10M
Depreciation and amortization 277.20M 278.50M 247.30M 218.00M 68.70M
Non operating income net other - - - - -
Operating income 98.10M 484.40M 270.80M 86.10M 117.40M
Other operating expenses 263.30M 775.30M 672.60M 662.10M 1692.90M
Interest expense 28.60M 15.50M 53.60M 0.10M 34.20M
Tax provision -17.30000M 122.90M 101.50M -25.60000M 24.80M
Interest income 62.30M 50.50M 62.90M 52.40M 25.10M
Net interest income -62.30000M -50.50000M -87.60000M 0.10M -34.20000M
Extraordinary items 12.20M 13.90M -22.60000M -142.50000M -1.90000M
Non recurring - - - - -
Other items - - - - -
Income tax expense -17.30000M 122.90M 101.50M -25.60000M 27.30M
Total revenue 1706.90M 2336.20M 1900.70M 1584.60M 1804.50M
Total operating expenses 1385.10M 1531.60M 1388.20M 1307.90M 1486.40M
Cost of revenue 223.70M 316.70M 270.60M 203.30M 206.50M
Total other income expense net -433.10000M -20.50000M 13.50M 2.60M -34.20000M
Discontinued operations 12.20M 13.90M -22.60000M -142.50000M -1.90000M
Net income from continuing ops -380.00000M 294.00M 66.30M 72.00M 55.90M
Net income applicable to common shares -367.80000M 307.90M 43.70M -70.50000M 55.30M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 2982.80M 3653.20M 4136.80M 3782.20M 4566.50M
Intangible assets - 73.10M 75.20M 76.30M 79.30M
Earning assets - - - - -
Other current assets 20.40M 31.60M 70.80M 40.80M 26.10M
Total liab 1942.10M 2147.00M 2215.20M 1924.90M 2635.20M
Total stockholder equity 1040.70M 1506.20M 1921.60M 1857.30M 1931.30M
Deferred long term liab - - - - -
Other current liab 128.10M 0.90M 5.70M 52.30M 447.90M
Common stock 2603.90M 2421.00M 2422.90M 2572.00M 2672.30M
Capital stock - 2421.00M 2422.90M 2572.00M 2672.30M
Retained earnings -1567.30000M -923.30000M -521.20000M -731.60000M -737.60000M
Other liab - 14.40M 18.60M 22.50M 74.20M
Good will 1296.70M 1897.50M 2344.30M 2042.30M 2040.20M
Other assets - 87.90M 74.60M 82.20M 82.40M
Cash 60.10M 115.30M 81.30M 70.10M 137.50M
Cash and equivalents - - - - -
Total current liabilities 600.30M 629.60M 641.30M 684.70M 972.80M
Current deferred revenue 0.00000M 147.70M 242.30M 196.50M 139.20M
Net debt 1537.80M 1650.70M 1697.70M 1372.00M 1619.90M
Short term debt 271.30M 263.00M 223.70M 230.00M 183.40M
Short long term debt - - - 5.60M 9.50M
Short long term debt total 1597.90M 1766.00M 1779.00M 1442.10M 1757.40M
Other stockholder equity -0.90000M -1497.70000M -1901.70000M -1844.00000M -1934.70000M
Property plant equipment - 1243.30M 1270.90M 1244.90M 1043.60M
Total current assets 300.10M 344.30M 371.80M 330.90M 1319.80M
Long term investments - 7.10M 5.80M 5.60M 1.20M
Net tangible assets - -464.40000M -497.90000M -261.30000M -188.20000M
Short term investments - - - - -
Net receivables 187.70M 164.60M 219.70M 184.10M 176.10M
Long term debt - 562.10M 606.10M 258.10M 810.10M
Inventory 31.90M 32.80M 49.20M 35.90M 26.90M
Accounts payable 200.90M 218.00M 169.60M 205.90M 202.30M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 5.00M 8.50M 19.90M 16.90M -3.40000M
Additional paid in capital - - - - -
Common stock total equity - - - - 2672.30M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - -3.60000M -
Accumulated amortization - - - - -
Non currrent assets other 71.80M - - - 8.00M
Deferred long term asset charges - - - - -
Non current assets total 2682.70M 3308.90M 3765.00M 3451.30M 3246.70M
Capital lease obligations - 1203.90M 1172.90M 1177.60M 937.80M
Long term debt total - 1503.00M 1555.30M 1211.30M 1574.00M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 67.30M -401.70000M 386.90M -121.90000M 9.90M
Change to liabilities 44.80M -33.60000M -57.60000M 61.40M 9.40M
Total cashflows from investing activities 67.30M -401.70000M 386.90M -121.90000M -217.50000M
Net borrowings -261.80000M 131.10M -758.80000M -171.40000M -66.00000M
Total cash from financing activities -366.60000M -176.50000M -984.70000M -192.60000M 125.70M
Change to operating activities -31.60000M 2.50M 34.40M 23.80M -17.20000M
Net income -367.80000M 307.90M 43.70M -70.50000M 55.90M
Change in cash 34.00M 8.60M -71.80000M 24.80M 35.70M
Begin period cash flow 81.30M 72.70M 144.50M 119.70M 84.00M
End period cash flow 115.30M 81.30M 72.70M 144.50M 119.70M
Total cash from operating activities 333.30M 586.80M 525.90M 406.90M 127.60M
Issuance of capital stock - - - - 244.00M
Depreciation 262.60M 265.00M 237.00M 246.10M 68.70M
Other cashflows from investing activities 143.40M -308.20000M -10.00000M -26.50000M -87.70000M
Dividends paid 34.30M 98.10M 56.30M 21.20M 52.30M
Change to inventory 14.50M -12.40000M -8.90000M -4.60000M 0.20M
Change to account receivables 52.60M -33.00000M 46.10M -74.40000M -18.60000M
Sale purchase of stock -8.90000M -139.40000M -97.50000M -97.50000M 244.00M
Other cashflows from financing activities -278.40000M 61.00M -242.00000M -171.40000M 130.00M
Change to netincome 431.80M 40.30M 127.20M 179.90M 42.00M
Capital expenditures 76.10M 93.50M 61.30M 72.40M 100.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 67.10M -45.40000M 37.20M -79.00000M 1.20M
Stock based compensation -7.80000M 7.90M 13.70M 9.60M -
Other non cash items 438.50M 13.90M 245.20M 231.30M -124.60000M
Free cash flow 257.20M 493.30M 464.60M 334.50M 27.60M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
HLS
Healius Ltd		 -0.025 1.75% 1.40 - 23.15 0.58 0.99 1.47 10.14
SHL
Sonic Healthcare Ltd		 -0.42 1.50% 27.50 26.26 26.74 1.51 1.72 1.95 10.52
IDX
Integral Diagnostics Ltd		 -0.08 2.68% 2.90 - 27.70 1.49 2.37 2.19 152.82
ACL
Australian Clinical Labs Ltd		 -0.12 3.32% 3.49 28.83 18.52 1.00 3.87 1.41 5.71
MVF
Monash IVF Group Ltd		 -0.015 1.21% 1.22 - 15.62 1.90 2.01 2.40 56.69

Reports Covered

Stock Research & News

View All

Profile

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics, QML Pathology, TML Pathology, Abbott Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories, medical centers, patient collection centers, and community imaging centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.

Healius Ltd

161 Castlereagh Street, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Dr. Malcolm W. Parmenter B.S., M.A.I.C.D., M.S. MD, CEO & Director 1955
Ms. Maxine Jaquet CFO & COO NA
Mr. John McKechnie Chief Exec. of the Pathology Division NA
Mr. Rob Phipps Group Exec. of People & Culture and Sustainability NA
Mr. Henry Barclay Chief Exec. of Day Hospitals NA
Mr. Charles Tilley B.Sc., FCIS, L.L.B., B.Sc. (Hons), LLB (Hons) Company Sec. NA
Ms. Alison Stephenson Additional Company Sec. NA
Ms. Janet Payne Group Exec. of Corp. Affairs NA
Dr. John Houston Advisor NA
Ms. Maxine Jaquet B.Com. MD, CEO & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.